AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02109965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2
Study NCT02624713 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: obesity treatment
Description: 1. Parents' education groups for nutrition and healthy behavior with a dietician and a social worker every 2 weeks for5 months, for a total of 10 meetings. This part of the intervention aimed at providing parents with effective tools for modification of lifestyle and the family environment.~2. Children's individual therapy consisted of 6 individual meetings with a family physician, a physical therapist specializing in children's physical activity, and a dietician. This part of the intervention aimed at modifying nutrition and lifestyle; the physical therapist can help children incorporate physical activity into their routine.~3. Physical activity groups for the children, with individual physical fitness monitoring. twice a week for 6 months. .
Study NCT02316652 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: Mechanical instrumentation
Study NCT02316652 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing with solution
Description: Mechanical instrumentation with sodium hypochlorite disinfective solution
Study NCT01363999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: single dose of atorvastatin on day 1
Study NCT01602900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK356278
Description: Investigational Medicinal Product
Study NCT01602900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolipram
Description: Challenge Agent
Study NCT00728325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported Employment (SE)
Description: SE(IPS)involves: a vocational rehabilitation employment specialist who is integrated into the clinical treatment team, carries out all phases of the vocational services, provides predominantly community-based services, provides assertive engagement and outreach, has a case load of ≤ 25 clients; engages in rapid job search, individualized placement in diverse and potentially permanent competitive job(s), ongoing work-based vocational assessment, and assistance in finding subsequent jobs if needed with the view that all jobs are positive learning experiences; continuous time-unlimited follow-along supports to provide vocational services; and weekly group supervision with IPS/VRP team and with IPS supervisor/trainer monthly.
Study NCT00728325 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Vocational Rehabilitation (VRP)
Description: Standard Vocational Rehabilitation (VRP) includes 1) the Vocational Assistance Program (includes routine prevocational testing and evaluation for all patients upon referral to VRP), 2) Vocational Rehabilitation Therapy that operates under the Compensated Work Therapy/Veterans Industries (CWT) and provides a work regimen with monetary incentives derived from contracts whereby participants are paid on a piece rate basis related to their production, and 3) Transitional Work Program (TWP) that includes a temporary work experience either within the VAMC or in community settings (called the Transitional Work External or TWE).
Study NCT01363999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalcetrapib
Description: single dose of dalcetrapib on day 1
Study NCT02134873 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sucrose
Description: Sucrose will be administered by a research nurse experienced in neonatal intensive care using a standardized procedure and timing consistent with policies in the participating units, including: (a) administering sucrose 2 minutes prior to the heel lance to ensure peak effects; (b) giving the total volume of sucrose drop by drop via syringe on the anterior surface of the tongue, as tolerated, over a period of up to 1 minute to allow for individual infant swallowing rates and to ensure analgesic effects are sustained during the heel lance procedure; and (c) offering a pacifier for non-nutritive sucking (NNS) immediately following sucrose administration.
Study NCT01809028 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS FNA with 2 passes
Description: biopsy with 2 passes
Study NCT01809028 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS FNA with 4 passes
Description: biopsy with 4 passes
Study NCT05267964 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epping resection arthroplasty
Description: Follwing the described epping resection arthroplasty, The first ray was immobilized using an orthosis for four weeks postoperatively in both study groups followed by eight weeks of physical therapy.
Study NCT05267964 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CMC I prosthesis
Description: Follwing the described CMC I prosthesis procedure, The first ray was immobilized using an orthosis for four weeks postoperatively in both study groups followed by eight weeks of physical therapy.
Study NCT01657994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined functional electrical stimulation and robotic gait training
Description: up to 18 sessions of approximately 45 minutes occurring over up to 9 weeks
Study NCT02885506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration of P218 capsules
Description: Oral administration of P218 capsules. The number of capsules is determined by the dose level of the cohort.
Study NCT02597556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: A single 400mg dose of Albendazole administered at 0, 3, 6, 9, and 12 months.
Study NCT02597556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet administered at 0, 3, 6, and 9 months. At month 12, all participants will receive a single dose of 400mg Albendazole.
Study NCT04297930 — intervention group
Intervention type: DEVICE
Intervention: Paul Glaucoma Implant Surgery
Description: This group of patients had glaucoma surgery with the Paul Glaucoma Implant
Study NCT01982253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasiglifam
Description: Fasiglifam tablets
Study NCT01982253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to fasiglifam
Description: Fasiglifam placebo-matching tablets
Study NCT01982253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to fasiglifam
Description: Fasiglifam placebo-matching tablets
Study NCT04374006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dienogest
Description: 1mg/kg BW/day based on the study by Katayama et al. A DNG in 0,5% carboxymethylcellulose suspension was given orally with metal sound daily 0,2-0,4 mL per day
Study NCT04374006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis
Description: The propolis contains 20 mg in each ml. So, each rat we given 0,2 ml for 50mg/kg propolis treatment and 0,4 ml for 100mg/kg propolis treatment
Study NCT04374006 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: we gave 0,2 ml to each rat everyday to negative control groups, and we gave no treatment to sham groups
Study NCT00913744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocriplasmin
Description: ocriplasmin intravitreal injection (125 µg)
Study NCT00913744 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham injection
Study NCT02808286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hybrid
Description: The hybrid emotion-focused treatment integrates procedures from exposure and dialectical behavior therapy (DBT) with a clear uniting conceptualization focused on targeting underlying processes that maintain co-occurring chronic pain and emotional problems.
Study NCT02808286 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: internet Cognitive Behavior Therapy (iCBT)
Description: A state-of-the-art CBT pain treatment, delivered via the internet.
Study NCT01275495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Assessment and Skill-Building Kit (TASK II)
Study NCT01275495 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information, Support, and Referral (ISR)
Study NCT01978314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 75 mg / 6 mL VFI™
Description: Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
Study NCT02061969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin
Description: 5mg linagliptin tablets
Study NCT02061969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Study NCT04242888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pragmatic manual therapies
Description: three of the intervention are novel and the rest of the interventions are in practice but seldom used to treat the shoulder disorder.
Study NCT00909948 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine and total body irradiation
Description: The patients in the second cohort will receive fludarabine 30 mg/m2/day on days -4 to -2 and 200 cGy TBI on day 0.
Study NCT00909948 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total body irradiation
Description: Patients will receive 200 cGy TBI on day 0,4-6 hours prior to HCT.
Study NCT04200248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBM-007 Injectable Solution
Description: RBM-007 Injectable Solution
Study NCT04200248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: EYLEA® (aflibercept) Injection, for Intravitreal Use
Study NCT04200248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: EYLEA® (aflibercept) Injection, for Intravitreal Use
Study NCT04200248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: Sham intravitreal injection
Study NCT04200248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham
Description: Sham intravitreal injection
Study NCT03528746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic Exercise
Description: Participants will complete dynamic leg extension in a leg extension machine with a range of motion from approximately 90 degrees flexion to full extension. Each repetition will be completed with a 3s concentric contraction, 0s isometric and 4s eccentric contraction.This will be repeated for 8 repetitions and for 5 sets with 2 minutes rest between each set, as per Rio and colleagues. The load used during the isotonic exercise will be equivalent to participants 8 repetition maximum, which will be determined by an experienced tester in a standardised manner according to NSCA guidelines.
Study NCT03528746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise
Description: Participants will complete isometric quadriceps exercise, where they must hold a load statically for 45s with their knee in 60° flexion. This will be repeated for 5 sets with 2 minutes rest between each set. A load of 70% of the maximal voluntary isometric contraction (MVIC) will be used. MVIC will be assessed in an isokinetic dynamometer as per Rio and colleagues. Participants will be seated in a stable position in the dynamometer with the knee at 60° of knee flexion. First they will be familiarised with the procedure. Standardised instructions will be issued for participants to perform a maximal effort knee extension against the dynamometer for 3seconds. After a short break, the test will be repeated three times and the MVIC will be peak torque recorded during these three efforts.
Study NCT00624962 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: nutritional intervention
Description: Nutritional status assessment on enrollment in study, beginning of course 1 and end of study period (week 12 or beginning of Course 5 chemotherapy)
Study NCT00721045 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Precursor Cells (MPCs)
Description: 25 M allogeneic MPCs by transendocardial injection and mapping.
Study NCT00721045 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Precursor Cells (MPCs)
Description: 75 M allogeneic MPCs by transendocardial injection and mapping.
Study NCT02885506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral administration of P218 matching placebo
Description: Oral administration of P218 matching placebo. The number of capsules is identical to the corresponding number of P218 capsules administered to the volunteers on the investigational drug.
Study NCT01992146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Target-controlled naloxone-infusion
Study NCT01992146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02516605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: LJN452
Description: LJN452 capsules administered once daily for 28 days
Study NCT02516605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part 1: Placebo
Description: Matching placebo capsules administered once daily for 28 days
Study NCT02516605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: LJN452 Dose level 1
Description: LJN452 capsules administered once a day for 12 weeks
Study NCT02516605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part 2: Placebo
Description: Matching placebo to LJN452 administered once a day for 12 weeks
Study NCT02516605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: LJN452 Dose level 2
Description: LJN452
Study NCT04675437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 12-weeks aerobic exercise program
Study NCT03334929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality headset
Description: The participants in this group would wear Virtual Reality headset called Oculus Gear VR during their trigger point injections.
Study NCT01935830 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11c] LAAM
Description: intravenous administration of 15-20 mCi of \[11c\] LAAM.
Study NCT01935830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Pretreatment with oral ritonavir for 3 days followed by intravenous administration of 15-20 mCI of \[11c\] LAAM.
Study NCT01935830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Pretreatment with oral Efavirenz 600 mg orally every night x 14 days followed by intravenous administration of 15-20 mCI of \[11c\] LAAM.
Study NCT04374006 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: we gave 0,2 ml to each rat everyday to negative control groups, and we gave no treatment to sham groups
Study NCT01438606 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSV-Indiana HIV gag vaccine
Description: Administered IM in both deltoids at baseline and Week 8. Dose will vary depending on which group the participant is enrolled in.
Study NCT01438606 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection (normal saline)
Description: Administered IM in both deltoids at baseline and Week 8.
Study NCT01640444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI + bevacizumab
Description: * Bevacizumab 5 mg/kg iv, followed by~* Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~* Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~* 5-FU 400 mg/m2 iv bolus, followed by~* 5-FU 2,400 mg/m2 for 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle).
Study NCT01640444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI + cetuximab
Description: * Cetuximab in an initial 120-minute infusion on day 1 of 400 mg/m2, followed by 60-minute infusions of cetuximab at a dose of 250 mg/m2, once weekly~* FOLFIRI:~  * Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~ * Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~ * 5-FU 400 mg/m2 iv bolus, followed by~ * 5-FU 2,400 mg/m2 for 46 h continuous infusion FOLFIRI will be given after the cetuximab infusion on day 1 of each period (every 2 weeks: 1 cycle).
Study NCT03314272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Space Glucose Control
Description: Development of a closed loop control system via Space Glucose Control that automatically infuses insulin on the basis of an automated algorithm, which integrates a continuous glucose signal, could help overcome these obstacles and permit strict glycemic control without increasing the workload.
Study NCT04701736 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Picture Medication Calendar
Study NCT02868957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: impression data from reference scanner
Description: To create a reference images for the assessment of the trueness, the impressions of the upper and lower arch of the oral cavities of four patients were taken using a polyether impression material (3M ESPE Soft Monophase; Minnesota Mining and Manufacturing Co.), and the intaglio scanning was performed on the impression body using a desktop scanner. Scanned images were transformed to the Standard Tessellation Language (STL) file format, and used as reference images.
Study NCT02868957 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTero
Description: The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of iTero intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner.
Study NCT02868957 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTero
Description: The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of iTero intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner.
Study NCT02868957 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trios
Description: The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of Trios intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner. .
Study NCT02868957 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trios
Description: The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of Trios intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner. .
Study NCT01962818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFOV combined with sigh breaths
Description: It is planned only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).~All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.~Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient wash-out period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh
Study NCT00108004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide acetate
Description: Pramlintide (0.6 mg/mL) in 5.0-mL multiple-draw glass vials for SC injection for 12weekes and after Pramlintide (1.0 mg/mL) 1.5 mL pen-cartridge. Subjects who do not switch to the pen-cartridge device at Week 12 will continue to administer pramlintide using a syringe and vial.
Study NCT03452943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-50717
Description: 6, 9, 12, 15, and 18 mg oral tablets
Study NCT03452943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to TEV-50717 tablets will be taken BID for 12 weeks.
Study NCT03452943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to TEV-50717 tablets will be taken BID for 12 weeks.
Study NCT00721045 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Precursor Cells (MPCs)
Description: 150 M allogeneic MPCs by transendocardial injection
Study NCT00721045 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: standard-of-care treatment with mock mapping and injection procedures.
Description: Mock
Study NCT03162874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: BID
Study NCT03865641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality rehabilitation
Description: Task-specific training has been shown to be more effective when tasks were ordered in a random practice sequence using repetition and positive feedback. VR is an interactive and enjoyable intervention. VR creates a virtual rehabilitation scene in which the intensity of practice can be systemically manipulated.